The dogma of cetuximab in advanced squamous cell carcinoma of the head and neck after failure of surgery and radiotherapy: is it true among patients in upper Egypt?

We aimed from the current study to explore the treatment results of cetuximab in combination with a weekly carboplatin and paclitaxel regimen in advanced squamous cell carcinoma of head and neck (HNSCC) after failure of radiotherapy and chemotherapy. This study was a non-randomised, single arm, phas...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Ecancermedicalscience 2023-10, Vol.17, p.1611
Hauptverfasser: Rayan, Amal, Shahine, Mohammed S, Rezk, Khalid, Zahran, Asmaa M, Aboshanif, Mohamed Modather, Gamal, Doaa A
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page 1611
container_title Ecancermedicalscience
container_volume 17
creator Rayan, Amal
Shahine, Mohammed S
Rezk, Khalid
Zahran, Asmaa M
Aboshanif, Mohamed Modather
Gamal, Doaa A
description We aimed from the current study to explore the treatment results of cetuximab in combination with a weekly carboplatin and paclitaxel regimen in advanced squamous cell carcinoma of head and neck (HNSCC) after failure of radiotherapy and chemotherapy. This study was a non-randomised, single arm, phase 2 efficacy study conducted in two oncology centres in upper Egypt, we recruited 31 patients with recurrent HNSCC previously treated with concurrent chemoradiation ± surgery to receive weekly cetuximab, carboplatin and paclitaxel for 18 weeks followed by maintenance cetuximab every 2 weeks for 12 months. All patients underwent intention to treat analysis. The current study revealed a significant reduction of the size of recurrent primary lesion ( < 0.001), without comparable significant reduction of regional lymph nodes (LNs) ( = 0.06), the current overall response rate (ORR) was 83.9%, ≥1-year progression-free survival (PFS) was 58.1%, also surgical intervention was succeeded to salvage 32.3% who did not achieve complete response to the current protocol, the median PFS was 12 months which was significantly affected by tumour site ( = 0.012), programmed death ligand-1 (PDL-1) expression ( = 0.01) and overall response rate (ORR) ( < 0.001). Based on favourable treatment outcomes, including high ORR and disease control rate, improved median PFS and tolerable toxicity profile, the current weekly cetuximab, carboplatin and paclitaxel with 1 year maintenance cetuximab in responding patients is considered a feasible and effective regimen.
doi_str_mv 10.3332/ecancer.2023.1611
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10898904</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2933373881</sourcerecordid><originalsourceid>FETCH-LOGICAL-c347t-a726779b65c8e8aaaa3c9eccc3b70ba17e6ff0bc539dd8e466430727d148ae823</originalsourceid><addsrcrecordid>eNpVkc1u1DAUhSMEoqXwAGyQJdYz2HFiO2wqVJUfqRKbsrZu7JuMSyZO_VMx78OD4jBDVbyxpXvOuUf-quoto1vOef0BDcwGw7amNd8ywdiz6pzJttkIQdvnT95n1asY7ygVrKvbl9UZVw1rOtGcV79vd0isH_dA_EAMpvzL7aEnbiZgH9Z4S-J9hr3PsYyniRgIxs3-aEjFvUOwBGZLZjQ_CQwJAxnATTngKok5jBgOfxUBrPPFE2A5fCQuEpdIChlJyZ9HskByOKe4bs_LUnKux8OSLl9XLwaYIr453RfVj8_Xt1dfNzffv3y7-nSzMbyRaQOyFlJ2vWiNQgXlcNOhMYb3kvbAJIphoL1peWetwkaIhlNZS8saBahqflFdHnOX3O_RmtIlwKSXUL4kHLQHp_-fzG6nR_-gGVWd6mhTEt6fEoK_zxiTvvM5zKW0rrvCTHKlWFGxo8oEH2PA4XEFo3olq09k9UpWr2SL593Tbo-Ofyj5H-_spOg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2933373881</pqid></control><display><type>article</type><title>The dogma of cetuximab in advanced squamous cell carcinoma of the head and neck after failure of surgery and radiotherapy: is it true among patients in upper Egypt?</title><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Rayan, Amal ; Shahine, Mohammed S ; Rezk, Khalid ; Zahran, Asmaa M ; Aboshanif, Mohamed Modather ; Gamal, Doaa A</creator><creatorcontrib>Rayan, Amal ; Shahine, Mohammed S ; Rezk, Khalid ; Zahran, Asmaa M ; Aboshanif, Mohamed Modather ; Gamal, Doaa A</creatorcontrib><description>We aimed from the current study to explore the treatment results of cetuximab in combination with a weekly carboplatin and paclitaxel regimen in advanced squamous cell carcinoma of head and neck (HNSCC) after failure of radiotherapy and chemotherapy. This study was a non-randomised, single arm, phase 2 efficacy study conducted in two oncology centres in upper Egypt, we recruited 31 patients with recurrent HNSCC previously treated with concurrent chemoradiation ± surgery to receive weekly cetuximab, carboplatin and paclitaxel for 18 weeks followed by maintenance cetuximab every 2 weeks for 12 months. All patients underwent intention to treat analysis. The current study revealed a significant reduction of the size of recurrent primary lesion ( &lt; 0.001), without comparable significant reduction of regional lymph nodes (LNs) ( = 0.06), the current overall response rate (ORR) was 83.9%, ≥1-year progression-free survival (PFS) was 58.1%, also surgical intervention was succeeded to salvage 32.3% who did not achieve complete response to the current protocol, the median PFS was 12 months which was significantly affected by tumour site ( = 0.012), programmed death ligand-1 (PDL-1) expression ( = 0.01) and overall response rate (ORR) ( &lt; 0.001). Based on favourable treatment outcomes, including high ORR and disease control rate, improved median PFS and tolerable toxicity profile, the current weekly cetuximab, carboplatin and paclitaxel with 1 year maintenance cetuximab in responding patients is considered a feasible and effective regimen.</description><identifier>ISSN: 1754-6605</identifier><identifier>EISSN: 1754-6605</identifier><identifier>DOI: 10.3332/ecancer.2023.1611</identifier><identifier>PMID: 38414964</identifier><language>eng</language><publisher>England: Cancer Intelligence</publisher><subject>Biopsy ; Cancer therapies ; Chemotherapy ; Clinical Study ; Head &amp; neck cancer ; Metastasis ; Neck ; Oncology ; Radiation therapy ; Squamous cell carcinoma ; Surgery ; Toxicity ; Tumors</subject><ispartof>Ecancermedicalscience, 2023-10, Vol.17, p.1611</ispartof><rights>the authors; licensee ecancermedicalscience.</rights><rights>the authors; licensee e cancermedicalscience. 2023. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>the authors; licensee cancermedicalscience. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10898904/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10898904/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38414964$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rayan, Amal</creatorcontrib><creatorcontrib>Shahine, Mohammed S</creatorcontrib><creatorcontrib>Rezk, Khalid</creatorcontrib><creatorcontrib>Zahran, Asmaa M</creatorcontrib><creatorcontrib>Aboshanif, Mohamed Modather</creatorcontrib><creatorcontrib>Gamal, Doaa A</creatorcontrib><title>The dogma of cetuximab in advanced squamous cell carcinoma of the head and neck after failure of surgery and radiotherapy: is it true among patients in upper Egypt?</title><title>Ecancermedicalscience</title><addtitle>Ecancermedicalscience</addtitle><description>We aimed from the current study to explore the treatment results of cetuximab in combination with a weekly carboplatin and paclitaxel regimen in advanced squamous cell carcinoma of head and neck (HNSCC) after failure of radiotherapy and chemotherapy. This study was a non-randomised, single arm, phase 2 efficacy study conducted in two oncology centres in upper Egypt, we recruited 31 patients with recurrent HNSCC previously treated with concurrent chemoradiation ± surgery to receive weekly cetuximab, carboplatin and paclitaxel for 18 weeks followed by maintenance cetuximab every 2 weeks for 12 months. All patients underwent intention to treat analysis. The current study revealed a significant reduction of the size of recurrent primary lesion ( &lt; 0.001), without comparable significant reduction of regional lymph nodes (LNs) ( = 0.06), the current overall response rate (ORR) was 83.9%, ≥1-year progression-free survival (PFS) was 58.1%, also surgical intervention was succeeded to salvage 32.3% who did not achieve complete response to the current protocol, the median PFS was 12 months which was significantly affected by tumour site ( = 0.012), programmed death ligand-1 (PDL-1) expression ( = 0.01) and overall response rate (ORR) ( &lt; 0.001). Based on favourable treatment outcomes, including high ORR and disease control rate, improved median PFS and tolerable toxicity profile, the current weekly cetuximab, carboplatin and paclitaxel with 1 year maintenance cetuximab in responding patients is considered a feasible and effective regimen.</description><subject>Biopsy</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Clinical Study</subject><subject>Head &amp; neck cancer</subject><subject>Metastasis</subject><subject>Neck</subject><subject>Oncology</subject><subject>Radiation therapy</subject><subject>Squamous cell carcinoma</subject><subject>Surgery</subject><subject>Toxicity</subject><subject>Tumors</subject><issn>1754-6605</issn><issn>1754-6605</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNpVkc1u1DAUhSMEoqXwAGyQJdYz2HFiO2wqVJUfqRKbsrZu7JuMSyZO_VMx78OD4jBDVbyxpXvOuUf-quoto1vOef0BDcwGw7amNd8ywdiz6pzJttkIQdvnT95n1asY7ygVrKvbl9UZVw1rOtGcV79vd0isH_dA_EAMpvzL7aEnbiZgH9Z4S-J9hr3PsYyniRgIxs3-aEjFvUOwBGZLZjQ_CQwJAxnATTngKok5jBgOfxUBrPPFE2A5fCQuEpdIChlJyZ9HskByOKe4bs_LUnKux8OSLl9XLwaYIr453RfVj8_Xt1dfNzffv3y7-nSzMbyRaQOyFlJ2vWiNQgXlcNOhMYb3kvbAJIphoL1peWetwkaIhlNZS8saBahqflFdHnOX3O_RmtIlwKSXUL4kHLQHp_-fzG6nR_-gGVWd6mhTEt6fEoK_zxiTvvM5zKW0rrvCTHKlWFGxo8oEH2PA4XEFo3olq09k9UpWr2SL593Tbo-Ofyj5H-_spOg</recordid><startdate>20231009</startdate><enddate>20231009</enddate><creator>Rayan, Amal</creator><creator>Shahine, Mohammed S</creator><creator>Rezk, Khalid</creator><creator>Zahran, Asmaa M</creator><creator>Aboshanif, Mohamed Modather</creator><creator>Gamal, Doaa A</creator><general>Cancer Intelligence</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>5PM</scope></search><sort><creationdate>20231009</creationdate><title>The dogma of cetuximab in advanced squamous cell carcinoma of the head and neck after failure of surgery and radiotherapy: is it true among patients in upper Egypt?</title><author>Rayan, Amal ; Shahine, Mohammed S ; Rezk, Khalid ; Zahran, Asmaa M ; Aboshanif, Mohamed Modather ; Gamal, Doaa A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c347t-a726779b65c8e8aaaa3c9eccc3b70ba17e6ff0bc539dd8e466430727d148ae823</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Biopsy</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Clinical Study</topic><topic>Head &amp; neck cancer</topic><topic>Metastasis</topic><topic>Neck</topic><topic>Oncology</topic><topic>Radiation therapy</topic><topic>Squamous cell carcinoma</topic><topic>Surgery</topic><topic>Toxicity</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rayan, Amal</creatorcontrib><creatorcontrib>Shahine, Mohammed S</creatorcontrib><creatorcontrib>Rezk, Khalid</creatorcontrib><creatorcontrib>Zahran, Asmaa M</creatorcontrib><creatorcontrib>Aboshanif, Mohamed Modather</creatorcontrib><creatorcontrib>Gamal, Doaa A</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Ecancermedicalscience</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rayan, Amal</au><au>Shahine, Mohammed S</au><au>Rezk, Khalid</au><au>Zahran, Asmaa M</au><au>Aboshanif, Mohamed Modather</au><au>Gamal, Doaa A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The dogma of cetuximab in advanced squamous cell carcinoma of the head and neck after failure of surgery and radiotherapy: is it true among patients in upper Egypt?</atitle><jtitle>Ecancermedicalscience</jtitle><addtitle>Ecancermedicalscience</addtitle><date>2023-10-09</date><risdate>2023</risdate><volume>17</volume><spage>1611</spage><pages>1611-</pages><issn>1754-6605</issn><eissn>1754-6605</eissn><abstract>We aimed from the current study to explore the treatment results of cetuximab in combination with a weekly carboplatin and paclitaxel regimen in advanced squamous cell carcinoma of head and neck (HNSCC) after failure of radiotherapy and chemotherapy. This study was a non-randomised, single arm, phase 2 efficacy study conducted in two oncology centres in upper Egypt, we recruited 31 patients with recurrent HNSCC previously treated with concurrent chemoradiation ± surgery to receive weekly cetuximab, carboplatin and paclitaxel for 18 weeks followed by maintenance cetuximab every 2 weeks for 12 months. All patients underwent intention to treat analysis. The current study revealed a significant reduction of the size of recurrent primary lesion ( &lt; 0.001), without comparable significant reduction of regional lymph nodes (LNs) ( = 0.06), the current overall response rate (ORR) was 83.9%, ≥1-year progression-free survival (PFS) was 58.1%, also surgical intervention was succeeded to salvage 32.3% who did not achieve complete response to the current protocol, the median PFS was 12 months which was significantly affected by tumour site ( = 0.012), programmed death ligand-1 (PDL-1) expression ( = 0.01) and overall response rate (ORR) ( &lt; 0.001). Based on favourable treatment outcomes, including high ORR and disease control rate, improved median PFS and tolerable toxicity profile, the current weekly cetuximab, carboplatin and paclitaxel with 1 year maintenance cetuximab in responding patients is considered a feasible and effective regimen.</abstract><cop>England</cop><pub>Cancer Intelligence</pub><pmid>38414964</pmid><doi>10.3332/ecancer.2023.1611</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1754-6605
ispartof Ecancermedicalscience, 2023-10, Vol.17, p.1611
issn 1754-6605
1754-6605
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10898904
source DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; PubMed Central Open Access
subjects Biopsy
Cancer therapies
Chemotherapy
Clinical Study
Head & neck cancer
Metastasis
Neck
Oncology
Radiation therapy
Squamous cell carcinoma
Surgery
Toxicity
Tumors
title The dogma of cetuximab in advanced squamous cell carcinoma of the head and neck after failure of surgery and radiotherapy: is it true among patients in upper Egypt?
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T22%3A17%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20dogma%20of%20cetuximab%20in%20advanced%20squamous%20cell%20carcinoma%20of%20the%20head%20and%20neck%20after%20failure%20of%20surgery%20and%20radiotherapy:%20is%20it%20true%20among%20patients%20in%20upper%20Egypt?&rft.jtitle=Ecancermedicalscience&rft.au=Rayan,%20Amal&rft.date=2023-10-09&rft.volume=17&rft.spage=1611&rft.pages=1611-&rft.issn=1754-6605&rft.eissn=1754-6605&rft_id=info:doi/10.3332/ecancer.2023.1611&rft_dat=%3Cproquest_pubme%3E2933373881%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2933373881&rft_id=info:pmid/38414964&rfr_iscdi=true